The FDA has granted breakthrough therapy designation to Bluejay Therapeutics’ brelovitug for the treatment of chronic hepatitis delta, for which no approved therapies currently exist in the U.S., the company announced in a press release. “Chronic hepatitis delta is the most aggressive form of viral hepatitis and the lack of approved treatments in the United States creates a major
KOLOA, Hawaii — Data from various retinal clinical trials suggest that there is a difference in efficacy in anti-VEGF therapies for patients with lower vision,…
Adults with type 2 diabetes using a GLP-1 drug have a similar risk for thyroid cancer as those using other diabetes drugs, though increased thyroid…
This clinical practice guideline from the American Society for Gastrointestinal Endoscopy (ASGE) provides an evidence-based approach for strategies to manage endoscopically placed gastrostomy tubes. This…
Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally tolerated it well, according to data published in The Lancet Respiratory…
We rarely discuss early trials, but this month we highlight a phase 2 trial that offers a promising new mechanism of action for our patients…
You’ve successfully added to your alerts. You will receive an email when new content is published. Back to Healio We were unable to process your…
Hepatitis B reactivation (HBVr) can occur due to a variety of immune-modulating exposures, including multiple drug classes and disease states. Antiviral prophylaxis can be effective…
Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable divergence with the recommended dosages of urate-lowering therapies, according…
Susan Weiner, MS, RDN, CDN, CDCES, FACES, talks with Brenda Jagatic, BScN, RN, CDCES, about the prevalence of erectile dysfunction for men with diabetes and…
